Cover Image

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline

Background: A new, effective anti-tuberculosis (TB) regimen containing bedaquiline (BDQ) and pyrifazimine (TBI-166) has been recommended for a phase IIb clinical trial. Preclinical drug-drug interaction (DDI) studies of the combination of BDQ and TBI-166 have been designed to support future clinical...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yangming Ding (Author), Haiting Liu (Author), Furun Wang (Author), Lei Fu (Author), Hui Zhu (Author), Shuang Fu (Author), Ning Wang (Author), Xiaomei Zhuang (Author), Yu Lu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy.
by: Aurélie Chauffour, et al.
Published: (2023)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
by: Leibert E, et al.
Published: (2014)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
by: Hu MH, et al.
Published: (2016)

Rezultatele tratamentului tuberculozei multidrogrezistente cu utilizarea bedaquiline şi delamanid
by: Rafig Bayramov, et al.
Published: (2021)

Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration
by: Sara E. Maloney, et al.
Published: (2023)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
by: Jing-Tao Gao, et al.
Published: (2021)

Synthesis, Characterization, and Stability Assessment for the Benzoate, Hydrochloride, Malonate, and Nicotinate Salts of Bedaquiline
by: Mercy A. Okezue, et al.
Published: (2023)

Assessing the safety of bedaquiline: insight from adverse event reporting system analysis
by: Jiaqiang Wu, et al.
Published: (2024)

The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data
by: Shanshan Li, et al.
Published: (2024)

The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran
by: Nahid Madadi-Goli, et al.
Published: (2024)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
by: Ge Shao, et al.
Published: (2023)

Evaluation of physicochemical stability and degradation kinetics of bedaquiline in hydrolytic solutions of different pH
by: S. J. Rajput, et al.
Published: (2021)

Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data
by: I Gusti Agung Ayu Putu Sri Darmayani, et al.
Published: (2022)

The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
by: Lisa Singh, et al.
Published: (2021)

The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis
by: Enyu Tong, et al.
Published: (2023)

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
by: Anna Starshinova, et al.
Published: (2022)

Feasibility and accuracy of mobile QT interval monitoring strategies in bedaquiline‐enhanced prophylactic leprosy treatment
by: Auke T. Bergeman, et al.
Published: (2024)

Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan
by: Asad Khan, et al.
Published: (2024)

Identification of urine biomarkers predictive of prolonged QTc interval in multidrug-resistant tuberculosis patients treated with bedaquiline
by: Jiajia Yu, et al.
Published: (2024)

Evaluation of the effectiveness of bedaquiline and delamanid treatment among children and adolescents with multi-drug-resistant pulmonary tuberculosis
by: M.I. Sakhelashvili, et al.
Published: (2023)

Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies
by: Mohammad A. M. Momin, et al.
Published: (2019)

The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats
by: Ruba S. Darweesh, et al.
Published: (2020)

Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
by: Lénaïg Tanneau, et al.
Published: (2021)

Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China
by: Yan Hu, et al.
Published: (2023)

In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats
by: Sandy Van Hemelryck, et al.
Published: (2019)

Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC)
by: Shehla Nasar Mir Najib Ullah, et al.
Published: (2023)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.
by: Juliano Timm, et al.
Published: (2023)

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam
by: Thi Mai Phuong Nguyen, et al.
Published: (2022)

A modeling‐based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
by: Lina Keutzer, et al.
Published: (2022)

Extensively drug-resistant tuberculosis treated with bedaquiline: A case report in the particularly vulnerable tribal group of Madhya Pradesh, India
by: Prashant Mishra, et al.
Published: (2021)

Whole Genome Sequencing for the Analysis of Drug Resistant Strains of <i>Mycobacterium tuberculosis</i>: A Systematic Review for Bedaquiline and Delamanid
by: Luisa Maria Nieto Ramirez, et al.
Published: (2020)

RP-HPLC method development and validation for bedaquiline fumarate to evaluate its forced degradation behaviour and stability in official dissolution media
by: Vishwas Pardhi, et al.
Published: (2020)

The Tramadol Metabolite O-Desmethyl Tramadol Inhibits Substance P-Receptor Functions Expressed in Xenopus Oocytes
by: Kouichiro Minami, et al.
Published: (2011)

In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats
by: Sandy Van Hemelryck, et al.
Published: (2021)

Clinical course of pregnancy and postpartum in a multidrug-resistant tuberculosis/HIV co-infected patient receiving bedaquiline-containing regimen as antimycobacterial therapy
by: О.М. Raznatovska, et al.
Published: (2019)

Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates
by: Wilson Poh, et al.
Published: (2019)

Quantitative Study of Impurities in Bedaquiline Fumarate: Identification and Characterization of Its Three Degradation Products Using HPLC, LC/ESI-MS, and NMR Analyses
by: Xiao-Wen Zhang, et al.
Published: (2023)

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2024)

Development of Bedaquiline-Loaded SNEDDS Using Quality by Design (QbD) Approach to Improve Biopharmaceutical Attributes for the Management of Multidrug-Resistant Tuberculosis (MDR-TB)
by: Rao Nargis Jahan, et al.
Published: (2023)